Uri Geiger
About Uri Geiger
Uri Geiger, age 57, is a Class III independent director of NeuroPace (NPCE) serving since January 2023, with his current term continuing until the 2027 Annual Meeting. He is Managing Partner of Accelmed Partners (medical device-focused private equity) and holds a Ph.D. in Economics from Columbia University’s Center for Law & Economics, with extensive board and investing experience in medtech. Core credentials include private equity governance, board leadership, and prior operating roles at Exalenz Bioscience and GalayOr Networks .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Exalenz Bioscience Ltd. | CEO; later Chairman | 2006–2008 | Led through sale to Meridian Bioscience |
| GalayOr Networks | Co-founder and CEO | 2001–2003 | Built optical components developer; sold to MEMSCAP |
| Dragon Variation Fund | Founding Partner | 2000–2007 | One of Israel’s first hedge funds; sold to Migdal |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Strata Skin Sciences, Inc. (public) | Director; Chairman (May 2018–Apr 2021; again from Oct 2023) | 2018–present | Board leadership in dermatology devices |
| Cogentix Medical, Inc. (public) | Chairman | Nov 2016–Apr 2018 | Led until sale (urology devices) |
| Various private medtech companies | Director | Ongoing | Portfolio and governance roles |
Board Governance
- Independence: Board affirmatively determined Uri Geiger is independent under Nasdaq rules .
- Committees: Member, Compensation Committee (Chair: Lisa Andrade); committee met 4 times in FY2024 .
- Attendance: Board met nine times in FY2024; each director (except a 2025 appointee) attended ≥75% of applicable meetings; independent directors hold executive sessions each quarterly board meeting .
- Class/Term: Class III director; term continues until 2027 Annual Meeting .
- Policies: Hedging, short sales, options, pledging/margin accounts prohibited for directors and employees (reduces alignment risk) .
Fixed Compensation
| Component | Policy Rate | Applicable to Geiger | Source |
|---|---|---|---|
| Board annual cash retainer | $40,000 | Yes | |
| Compensation Committee member retainer (non-Chair) | $7,500 | Yes | |
| Committee Chair fees | $15,000 (Comp); $20,000 (Audit); $10,000 (Nominating) | Not applicable | |
| Chair of the Board additional retainer | $35,000 | Not applicable | |
| Meeting fees | Not specified | Not applicable | |
| Reimbursement of reasonable expenses | As incurred | Eligible | |
| 2024 Fees Earned or Paid in Cash (reported) | $47,500 | Elected RSUs in lieu of cash |
Notes:
- Geiger elected fully vested RSUs in lieu of cash retainers: 5,201 RSUs for FY2024 .
Performance Compensation
| Equity Component | 2024 Grant Value | Vesting Schedule | Change-in-Control Treatment |
|---|---|---|---|
| Annual non-employee director stock option | $77,159 | Vests upon earlier of one-year from grant or immediately prior to the next annual meeting | All outstanding non-employee director options fully vest upon a change in control |
No performance metrics tied to director compensation were disclosed; director equity is time-based and/or annual-meeting based vesting .
Other Directorships & Interlocks
| Company | Type | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Strata Skin Sciences, Inc. | Public medtech | Director; former and current Chairman | None disclosed with NPCE’s customer/supplier base |
| Cogentix Medical, Inc. | Public medtech (sold) | Chairman | Past role; no active interlock |
| Accelmed Partners II LP | Private equity fund | Managing Partner | Accelmed is a 13.5% beneficial owner of NPCE—board representation plus significant ownership may create influence considerations |
Expertise & Qualifications
- Medical device industry investing and board leadership (Accelmed Partners; multiple medtech boards) .
- Prior operator experience (CEO/chair roles at Exalenz; CEO/co-founder at GalayOr) .
- Economics Ph.D. focused on global equity markets (Columbia University Center for Law & Economics) .
Equity Ownership
| Holder | Shares Owned | Options/RSUs Exercisable/Vesting ≤60 Days | Total Beneficial Ownership | % Outstanding | Notes |
|---|---|---|---|---|---|
| Uri Geiger | 4,443,844 | 142,240 | 4,586,084 | 13.9% | Includes shares held by Accelmed Partners II LP, for which Geiger is managing partner; Accelmed entities own 4,432,948 shares (13.5%) |
Company policy prohibits pledging and hedging; no pledges disclosed for Geiger .
Insider Trades (Form 4)
Director Compensation Details (FY2024)
| Name | Fees Earned or Paid in Cash ($) | Option Awards ($) | Total ($) | RSUs in lieu of cash (shares) |
|---|---|---|---|---|
| Uri Geiger | 47,500 | 77,159 | 124,659 | 5,201 |
As of December 31, 2024, Geiger held options to purchase 165,675 shares of NPCE common stock . Non-employee director options vest on the earlier of one year or immediately before the next annual meeting; all such options fully vest upon a change in control .
Governance Assessment
-
Strengths
- Independent director with meaningful medtech investing and operating experience; significant skin-in-the-game via Accelmed’s 13.5% stake and personal options, aligning interests with shareholders .
- Active Compensation Committee member; committee uses independent compensation consultants (Compensia in early 2024; Alpine currently) with no conflicts identified; regular executive sessions support independent oversight .
- Attendance threshold met (≥75%); robust insider trading policy prohibiting hedging and pledging reduces misalignment risk .
-
Potential Conflicts / Red Flags
- Accelmed Partners II LP is a 13.5% beneficial owner with Geiger as managing partner; his presence on the Compensation Committee could raise perceived influence risks from a major shareholder, though the Board affirms independence and the Audit Committee oversees related party transactions .
- No related-party transactions disclosed involving Accelmed; continued monitoring advisable given ownership concentration .
-
Other Signals
- Election to receive RSUs in lieu of cash indicates equity alignment; director equity awards are time-based rather than performance-based (appropriate for non-employee directors) .
Notes and References
- Board structure, independence, committees, attendance, policies: .
- Director biography and external roles: .
- Beneficial ownership and percentage outstanding: .
- Director compensation policy and annual awards: .
- Insider trades pulled from SEC Form 4 filings (citations via SEC URLs in table above).